analyzing response to desmopressin in patients with type 2n von willebrand disease
Published 11 months ago • 374 plays • Length 2:12Download video MP4
Download video MP3
Similar videos
-
14:25
an overview of novel innovative treatments for patients with von willebrand disease
-
2:33
unmet needs and emerging treatments in von willebrand disease
-
0:52
unmet needs and emerging approaches in the treatment of von willebrand disease
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
0:42
the role of von willebrand factor in scd: predicting complications
-
3:02
durability of response & biomarker changes in the manifest study
-
2:43
interim analysis of the elm-2 study: odronextamab in patients with r/r follicular lymphoma
-
2:57
imetelstat for lr-mds: insights from the imerge trial
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
2:16
updates in the myelodysplastic syndromes: 2023 best of hematology
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
2:06
understanding the role of inflammation and the immunome in mds pathophysiology
-
1:17
phase ii study of tosedostat in mds
-
2:26
assessing the impact of momelotinib on transfusion burden in mf: analysis of simplify-1 & momentum
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:47
improving the assessment of response in relapsed mm
-
1:06
assessing metabolic tumor volume as a prognostic marker before car-t therapy for dlbcl
-
0:45
difference between quality of life & patient-reported outcomes
-
3:25
refined diagnostic criteria for sos/vod in adult patients: 2023 update by the ebmt
-
3:10
is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for mcl?
-
2:41
bomedemstat combined with ruxolitinib for the treatment of mf: early results of a phase ii trial
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study